Key Specifications Table
|Empirical Formula||CAS #|
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|382173-5MG||Plastic ampoule||5 mg||
|Overview||A cell-permeable p-tolylbenzamide and a Histone Deacetylase (HDAC) Inhibitor IV (Cat. No. 382170) analog that acts as a selective inhibitor against class I HDAC1,2,3 (IC50 = 0.15, 0.76, and 0.37 µM with 15, 30, and 180 min preincubation, respectively), while exhibiting much lower acitivity against class I HDAC8 (IC50 ≥ 5µM with 3 h preincubation) and no activity against class II HDAC4/5/7 even at concentrations as high as 180µM. Although the mode of inhibition is mechanistically competitive and reversible, due to the slow- and tight-binding nature, long preincubation is often required for effective in vitro enzyme inhibition, while 106-induced cellular H3 hyperacetylation is shown to persist for more than 6 hours after inhibitor removal by washing in GM15850 culture. 106 is reported to be less cytotoxic than TSA (Cat. No. 647925), MS-275, and SAHA (EC50 = 6.3, 0.328, 0.768, and 1.5 µM, respectively, in GM15850 killing).|
|Synonyms||N¹-(2-Aminophenyl)-N⁷-p-tolylheptanediamide, Pimelic Diphenylamide 106|
|References||Chou, C.J., et al. 2008. J. Biol. Chem. 283, 35402.|
|Structure formula Image|
|Purity||≥95% by HPLC|
|Safety Information according to GHS|
|S Phrase||S: 22-24/25-36
Do not breathe dust.
Avoid contact with skin and eyes.
Wear suitable protective clothing.
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Chou, C.J., et al. 2008. J. Biol. Chem. 283, 35402.|
|White Paper - The Message in the Marks: Deciphering Cancer Epigenetics (EMD)|